-+ 0.00%
-+ 0.00%
-+ 0.00%

Moleculin Biotech Announces 45th Enrollee In Phase2B/3 Trial For Annamycin Plus Cytarabine As A Treatment For Relapsed Or Refractory Acute Myeloid Leukemia

Benzinga·03/23/2026 12:43:19
Listen to the news

This milestone triggers the final phase of preparation for the trial's interim 45 subject data unblinding, which remains on track for mid-2026 and represents a potentially defining inflection point for the Company.